The Melanocortin System: PT-141 and Melanotan II in the Literature

The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R) that bind a family of endogenous peptides derived from proteolytic processing of pro-opiomelanocortin (POMC). The receptor-tissue mapping is the central pharmacological framework: MC1R on melanocytes mediates skin and hair pigmentation; MC2R on the adrenal cortex mediates corticosteroid synthesis; MC3R and MC4R in the central nervous system regulate energy balance, appetite, and sexual response; and MC5R in exocrine glands and lymphocytes has a less-well-characterized role.

The endogenous ligand for MC1R, MC3R, MC4R, and MC5R is α-melanocyte-stimulating hormone (α-MSH); for MC2R it is adrenocorticotropic hormone (ACTH). Synthetic analogs that target individual receptor subsets — particularly MC4R — are the basis for the pharmacology discussed below.

Melanotan II is a cyclic heptapeptide analog of α-MSH developed in the 1980s at the University of Arizona. The structure includes a lactam bridge between residues 5 and 10 that constrains the active conformation, and substitutions that improve receptor-binding affinity. The compound is a non-selective agonist at MC1R, MC3R, MC4R, and MC5R.

The non-selectivity defines the pharmacology. MC1R engagement on dermal melanocytes produces eumelanin synthesis and skin darkening — the original development rationale for the compound, as a "sunless tanning" agent. MC4R engagement in the central nervous system produces appetite suppression and sexual response, leading to the secondary observation that the peptide affects sexual function. MC3R and MC5R contributions to the overall profile are less well-characterized.

Melanotan II was never advanced to regulatory approval. Development of selective analogs targeting individual receptors — most importantly PT-141 / bremelanotide at MC4R and afamelanotide at MC1R — derives from the recognition that the non-selective profile produced both the desired effects and the off-target effects observed with the parent compound.

PT-141 (bremelanotide) is the MC4R-selective successor to melanotan II. The structure retains the cyclic heptapeptide backbone but introduces modifications that produce preferential activity at MC4R with reduced activity at MC1R — the receptor responsible for the pigmentation effect.

MC4R is expressed in the medial preoptic area of the hypothalamus and the paraventricular nucleus, where activation engages downstream dopaminergic and oxytocinergic pathways regulating sexual arousal. The pharmacology is mechanistically distinct from PDE5 inhibitors, which act on peripheral vascular tissue — PT-141 acts centrally on the upstream signaling pathway for sexual response.

Bremelanotide (brand name Vyleesi) was approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT Phase 3 program established efficacy versus placebo on validated patient-reported outcome measures. This makes bremelanotide the most extensively characterized clinically of any melanocortin agonist, and the central reference compound for the receptor pharmacology.

For completeness: afamelanotide (Scenesse) is an MC1R-selective melanocortin agonist approved for erythropoietic protoporphyria, a rare genetic disorder in which UV-induced phototoxicity is the primary clinical problem. The compound increases eumelanin synthesis and provides photoprotection.

Afamelanotide is not discussed in detail here because the indication is narrow and the receptor selectivity is the opposite of PT-141 — but it establishes that the MC1R arm of the melanocortin system has its own approved pharmacology distinct from the MC4R-centered work.

For a practitioner reading the literature, the clearest framing is: melanotan II is the parent non-selective compound, with effects at all four broadly expressed melanocortin receptors and a profile dominated by pigmentation (MC1R) and central effects (MC4R). PT-141 is the MC4R-selective successor, with central effects on sexual response preserved and the pigmentation effect substantially reduced. The clinical record reflects this distinction: melanotan II is not approved anywhere; PT-141 (bremelanotide) holds FDA approval in a specific indication.

Discussions that conflate the two compounds — treating PT-141 as "the next melanotan" or melanotan II as "an alternative to bremelanotide" — miss the receptor pharmacology that distinguishes them.

The most important open question for the MC4R-centered work is the extent to which central melanocortin signaling can be engaged for indications beyond HSDD. Energy balance and appetite regulation is an active research area, with setmelanotide (Imcivree) — an MC4R agonist approved for genetic obesity syndromes including POMC, PCSK1, LEPR, and Bardet-Biedl syndrome — establishing that MC4R agonism produces clinically meaningful weight effects in MC4R-pathway disorders.

Whether MC4R agonism produces clinically meaningful effects in non-genetic obesity is less established, and is a separate question from the incretin-based pharmacology dominating the broader metabolic conversation.